About HUILUN

Shanghai Huilun Pharmaceutical Co., Ltd. is an innovative pharmaceutical company. Through years of continuous effort, we have established an integrated operational system encompassing the pharmaceutical value chain from R&D and manufacturing to commercialization, with a strategic focus on innovative drugs targeting major diseases and critical illnesses.

Since our establishment, we have focused on areas such as immunology and inflammation, pain management, oncology, and other chronic conditions. Our expertise in disease biology has enabled us to advance four Category I innovative drugs and three Category II modified new drugs into clinical trials.

Meanwhile, we have successfully commercialized more than ten drug products in China, including Xiweina (希为纳®), the only domestically developed sivelestat sodium approved in China. We remain committed to developing safe, effective and economically accessible therapies that deliver high clinical value and continuously address unmet medical needs.